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Abstract  
Objective: 
Glutathione (GSH) has a central role in the defence against oxidative damage. This study 
was carried out to investigate any change in erythrocyte GSH levels in a population of 
patients with acute myocardial infarction (AMI) and compare them with levels in normal 
healthy subjects. 
Method: 
GSH levels were determined in erythrocytes of one hundred and seventy six patients with 
AMI (age: 30-70 years; 131 males and 45 females) admitted to the National Institute of 
Cardiovascular Diseases, Karachi. These levels were compared with eryrocyte GSH 
levels obtained from 95 normal healthy subjects (controls). 
Results: 
Mean ± SD erythrocyte GSH levels in AMI patients and controls were found to be 2.34 ± 
0.62 µmol/ml of packed cells and 2.08± 0.62 µmol/ml of packed cells, respectively. The 
two values when compared with one way ANOVA were found to be significantly 
different (p=0.001). Age had little effect on erythrocyte GSH levels in both AMI patients 
and normal healthy subjects. 
Conclusion: 
Increased production of reactive oxygen species is a feature of cardiovascular disease, such as 
AMI and cells can respond to mild oxidative stress by upregulating antioxidant defence in terms 
of increased production of GSH (JPMA 54:254;2004). 
Introduction  
Glutathione is an important endogenous antioxidant in the human body. It protects cells from toxic 
effects of reactive oxygen compounds.1 A number of studies have demonstrated that blood 
glutathione (GSH) could be a predictor of mortality and morbidity, because low blood glutathione 
values have been associated with a number of clinical disorders including diabetes2,3, chronic 
renal failure4 malignancies5, Parkinson's disease6, cataract formation7,8 and HIV infection.9,10 
However, the data on the correlation between the blood levels of GSH and the ischemic process 
is quite controversial. Usal et al11 have reported 3.8% depressed levels of total erythrocyte GSH 
in patients with acute myocardial infarction (AMI) compared to normal healthy subjects whereas 
Mills et al12 have shown no change in GSH levels in blood of patients with cardiovascular 
disease. The present study was undertaken to investigate any change in the erythrocyte GSH 
levels in a Pakistani population of AMI patients as compared to normal healthy subjects. 
 
Patients & Methods  
One hundred and seventy six consecutive Pakistani patients with AMI (age 30-70 years) admitted 
to the National Institute of Cardiovascular Diseases (NICVD), Karachi from January to June 2001, 
were selected for this study. They had confirmed diagnosis of AMI on the basis of clinical history, 
ECG and biochemical data and were not taking any vitamin supplementations during the past 6 
months. Those cases who were found to be pregnant, using antiepileptics, oral contraceptives, 
having malabsorption syndrome, suffering from tuberculosis, liver disease, uremia, or cancer 
were not included in the study. 
 
Similarly, 95 normal healthy subjects belonging to the same socio-economic class, were selected 
from the personnel of the Aga Khan University and Civil Hospital, Karachi for this study. Informed 
consent was obtained from the participants and the study was approved by the Ethical Committee 
of the Aga Khan University. 
 
A stringent criteria was used for the selection of normal healthy control subjects. In addition to 
being matched for sex, socio-economic background, and to some extent for age they had no 
evidence of coronary artery disease (CAD), diabetes mellitus, hypertension, obesity and 
hypercholesterolemia. Those control subjects who were found to be pregnant; using 
antiepileptics, oral contraceptives; having malabsorption syndrome; suffering from tuberculosis, 
uremia or liver disease, were excluded from this study. 
 
Determination of GSH level  
 
Five millilitres venous blood collected from patients as well as from normal healthy subjects was 
transferred immediately to EDTA containing tubes. Samples were centrifuged at 1500g for 5 
minutes. Plasma was carefully removed and an aliquot (10µl) of packed erythrocytes was 
removed and analyzed for total GSH by a modification of the method by Tietze.13 
 
Briefly, 10µl of packed erythrocytes were added to 0.99 ml of cold 0.01M phosphate buffer, pH 
7.5, containing 0.005M EDTA. For analysis, 25µl of the resulting hemolysate was added to a 
reaction mixture containing 975µl of 0.01M phosphate/0.005M EDTA buffer, pH7.5, 50µl of 5, 5´-
dithiobis-(2-nitrobenzoic acid) (DNTB) and 40µl of glutathione reductase (6 units/ml). After mixing 
at room temperature, 50µl of NADPH (4mg/ml) was added to  
Table 1. Demographic and clinical characteristics of subjects  
Varible    Controls (n=95)    Patients (n=176)    
   Value  Frequency  Value  Frequency  P-value  
   (mean + SD)  (%)  (mean + SD)  (%)     
 
                  
Age (years)  45.93 + 8.6     50.96 + 8.3     0.0001  
Gender                 
Male     76 (80%)     131 (74.4%)  0.3  
Female     19 (20%)     45 (25.6)     
BMI (kg/m2)  24.11 + 4.62     24.51 + 3.6     0.431  
Glucose (mg/dl)  102.94 + 21     140 + 72     0.0001  
Cholesterol (mg/dl)  173 + 28     186 + 47     0.022  
Smoking status                 
Smoker     13 (13.7%)     77 (43.8%)  0.0001  
Non-smoker     82 (86.3%)     99 (56.3%)     
Diet                 
Vegetarian     2 (2.%)     1 (0.6%)  0.59  
Non-vegetarian     93 (97.9%)     175 (99.4%)     
Parental history of IHD                 
Yes     21 (22.1%)     42 (23.9%)  0.74  
No     74 (77.9%)     134 (76.1%)     
Hypertensive                 
Yes     0     117 (66.5%)     
No     95 (100%)     59 (33.5%)     
Diebetic                 
Yes     0     71 (40.3%)     
No  95 (100%)  105 (33.5%)           
                  
 
*P value compares the mean or percentage values in controls with values in patients.  
the reaction and the rate of change in OD at 412 nm was monitored using a DU-70 
spectrophotometer (Beckman Instruments Inc., Palo Alto., CA). A standard curve ranging 
0.5nmol-2nmol GSH in 10mM perchloric acid in the above mentioned phosphate buffer was run 
along with the unknown samples. The standard curve was plotted using concentration of GSH 
and the rate of change in OD as ordinates. The value of GSH in the unknown sample was 
determined using this standard curve. Concentration of GSH was expressed as µmol/100ml of 
packed red cells. 
 
Statistical analysis  
 
All mean values are expressed as mean ± SD. Percentages were compared by using chi-square. 
Mean values of various groups were compared using one way analysis of variance (ANOVA). 
The analyses were performed with the statistical package (Epi Info 6, version  
Table 2. Glutathione levels in erythrocytes of normal healthy subjects and AMI patients  
Variable  Controls    Patients    P Value(a)  
   n  GSH  n  GSH   
    
(umol/ml of packed 
cells)   
(umol/ml of packed 
cells)     
 
Male  76  2.09 + 0.65  131  2.32 + 0.62  0.01  
Female  19  2.0 + 0.45  45  2.37 + 0.59  0.02  
Smokers  13  2.0 + 0.58  77  2.31 + 0.63  0.01  
Non-smokers  82  2.09 + 0.62  99  2.35 + 0.61  0.0005  
Diabetics  0   71  2.30 + 0.6   
Non-diabetics  95  2.08 + 0.62  105  2.36 + 0.6  0.001  
Hypertensive  0   117  2.23 + 0.61(b)   
Non-hypertensive  95  2.08 + 0.62  59  2.52 + 0.56b  0.0001  
Age > 50 years  64  2.07 + 0.59(c)  84  2.27 + 0.6(c)  0.045  
< 50 years  31  2.1 + 0.69(c)  92  2.4 + 0.63(c)  0.022  
 
(a)  P-value compares the mean GSH levels in controls with patients using one way ANOVA.  
(b)  A comparison of the mean GSH values in hypertensive patients and normotensive patients revealed a significant difference (P=0.0001)  
(C)  A comparison of mean GSH values below and above 50 years within each group (patients or controls) showed no significant difference.  
6.04 d, 2001, WHO). A p-value less than 0.05 was considered significant. 
 
Results  
Demographic and clinical characteristics of the patients have been listed in Table 1. Among the 
patients there were 131 males and 45 females, while among the normal healthy subjects 76 were 
males and 19 females. Mean age of AMI patients was 50.96±8.3 years, while mean age in normal 
controls was 45.93±8.6 years. The two values were statistically different indicating that AMI 
patients and normal healthy subjects were not exactly matched for age in this study. Mean body 
mass index (BMI) values for both patients and normal healthy subjects were nearly same 
(24.5±3.6 vs 24.1±4.6, respectively). Mean levels of fasting serum glucose in patients and 
controls were 140±72 mg/dl and 102±21 mg/dl, respectively. The two values when compared by 
one way ANOVA were found to be significantly different. Proportion of smokers among patients 
was higher than controls (p=0.0001). Serum cholesterol levels in the two groups were 
significantly different, while parental history of ischemic heart disease (IHD) was nearly the same 
in normal healthy subjects and AMI patients. 
Figure shows the concentration of erythrocyte GSH in AMI patients and normal healthy subjects 
(controls). The levels in AMI patients and controls were found to be 2.34±0.62µmol/ml of packed 
red cells and 2.08±0.62µmol/ml of packed red cells, respectively. The two values when compared 
with one way ANOVA were found to be statistically significant (p=0.001). 
Table 2 shows glutathione levels in erythrocytes of AMI patients and normal healthy subjects 
relative to their age, gender, smoking status, blood pressure, being diabetic or nondiabetic. With 
the exception of the smokers category, erythrocyte GSH values in all other listed categories (such 
as age, gender, diabetes and blood pressure) were significantly higher in the patients group 
compared to normal healthy subjects. 
A comparison of the mean GSH values above and below 50 years within the patients group or 
within the control group revealed no statistically significant difference indicating that aging has 
little effect on total erythrocyte GSH levels. These results are in conformity with those reported by 
Samiec et al14 and Richie.15 
Discussion  
GSH has a central role in the defence against oxidative damage. The balance between 
production of free radicals and antioxidant deficiencies in the body (such as GSH) has important 
health implications. If there are many free radicals produced and too few antioxidants, a condition 
of "oxidative stress" develops which may cause damage to the tissue. 
 
Previous studies have shown that erythrocyte GSH is decreased in diabetes2, liver disease16, 
Parkinson's disease6,17, myocardial infarction11 and old age.18 However, Samiec et al14 
showed that in age-related pathologies oxidation of GSH was more important than a decline in 
pool size of GSH, while in specific pathologies such as, diabetes both oxidation and a decline in 
pool size might be important. Decrease in total GSH pool could occur, in part, because of 
decreased synthesis of GSH due to decreased activity of gamma-glutamylcysteine synthase as 
has been previously reported in erythrocytes of diabetics.3 However, in certain conditions of 
oxidative stress, there is an increase in total GSH to boost the antioxidant defence mechanism of 
the body.19 Moreover, GSH has also been reported to increase the vasodilation of coronary 
artery when added to isolated and perfused rodent heart.20 On these observation, it is plausible 
that the observed increase in total GSH in our patients is in response to the oxidative stress due 
to AMI. 
Smith et al.21 have also reported an increase in antioxidant defences in terms of increased levels 
of GSH in bronchiolar lavage fluid from patients with asthma. In animal model too, concentration 
of GSH has been found to increase in response to cigarette smoke and alcohol.22 
Our results pertaining to increased levels of total GSH in AMI patients are different from those 
reported by Usal et al15, who have reported decreased levels of GSH in erythrocytes. This could 
be due to the fact that their data was on relatively small number of patients (n=21). Moreover, 
their maximum observed mean decrease in GSH was 11.5% on day 2 after MI and 3.8% on the 
following days. Our sample size was large (n=176) and we monitored GSH in patients within 24 
hours after infarction. There is a possibility that with increased time interval after infarction, the 
levels of GSH may decline due to severe oxidative stress which can damage DNA, proteins and 
lipids leading to cell death by apoptotic or necrotic mechanisms.23 
In conclusion, it can be said that increased production of reactive oxygen species is a feature of 
cardiovascular disease and cells can respond to mild oxidative stress by up-regulating antioxidant 
defence. The data in this study is suggestive that induction of GSH could be one of these 
mechanisms in AMI. 
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